CureVac says preliminary trials show Covid-19 vaccine effective against variants

Published on Feb 25, 2021 10:28 PM IST

CureVac chief Haas told EU lawmakers that the results of the preliminary trials on the vaccine's effects on variants would be published soon.

Vials are seen on a packing line of the factory of British pharmaceutical company GlaxoSmithKline (GSK) in Wavre on February 8, 2021 where the Covid-19 CureVac vaccine will be produced.(AFP)
Vials are seen on a packing line of the factory of British pharmaceutical company GlaxoSmithKline (GSK) in Wavre on February 8, 2021 where the Covid-19 CureVac vaccine will be produced.(AFP)
Reuters |

CureVac chief Franz-Werner Haas said on Thursday that preliminary trials on animals of the company's Covid-19 vaccine candidate show it is effective against the UK and South African variants.

Haas told EU lawmakers that the results of the preliminary trials on the vaccine's effects on variants would be published soon.

He also said that the company expected its vaccine to be approved in the European Union by June. (Reporting by Francesco Guarascio @fraguarascio; Editing by Susan Fenton)

Get Latest World News along with Latest News from Indiaat Hindustan Times.
SHARE THIS ARTICLE ON
SHARE
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Saturday, October 01, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals